Erika Hamilton, Director of Breast Cancer Program at Sarah Cannon Research Institute, shared a post on X:
“DatoDXd – FDA approved 1st line TNBC among pts who are not a candidate for immunotherapy. Not 1, not 2, but now 3 approvals in BCSM this month!”
Kelly Shanahan, Director at METAvivor Research And Support, shared Erika Hamilton’s post, adding:
“And we have another option for metastatic TNBC! Research for the win. We still have a long way to go across all subtypes for more effective, less toxic therapies.”
Dato-DXd Plus Durvalumab Shows Durable First-Line Activity in Advanced TNBC
